Kuros Biosciences USA, Inc. Announces an Exclusive Strategic Agreement With the Medtronic Spinal Division
Kuros Biosciences USA, Inc. Announces an Exclusive Strategic Agreement With the Medtronic Spinal Division
Medtronic will act as the exclusive sales agent of MagnetOsTM for Kuros Biosciences USA, Inc. in mutually agreed upon sales territories for use in spine surgeries
Kuros will work collaboratively to sell, market and provide support services to Medtronic's sales force
Kuros will keep responsibility for contracts, hospital partnerships and the recognition of revenue from sales
Kuros will continue to sell directly in non-contracted territories as well as in markets outside of spine
This agreement transforms an initial trial agreement into a strategic alliance
美敦力将作为Kuros Biosciences USA, Inc.在双方商定的销售区域内的MagnetsTm独家销售代理，用于脊柱手术。
Kuros将与美敦力的销售团队合作销售、营销并提供支持服务。
Kuros将继续负责合同、医院伙伴关系以及销售营收的确认。
Kuros将在非合同区域以及脊柱以外的市场继续直接销售。
这项协议将初步的试用协议转变为战略联盟。
SCHLIEREN, SWITZERLAND / ACCESSWIRE / January 7, 2025 / Kuros Biosciences USA Inc., ("Kuros"), a wholly owned subsidiary of Kuros Biosciences AG, a global leader in advanced musculoskeletal bone healing technologies, today announced a strategic five-year, exclusive sales agency agreement with Medtronic, a leading global healthcare technology company. The agreement provides Medtronic with exclusivity in certain spine geographies within the U.S. market, underscoring a shared commitment to expanding access to Kuros' pioneering MagnetOs bone grafting technology.
瑞士施利伦 / ACCESSWIRE / 2025年1月7日 / Kuros Biosciences USA Inc.（"Kuros"），Kuros Biosciences AG的全资子公司，全球领先的爱文思控股骨愈合技术公司，今天宣布与美敦力签署一项为期五年的战略独家销售代理协议。该协议为美敦力在美国市场某些脊柱地区提供了独占性，强调了双方扩大Kuros开创性的MagnetOs骨移植技术获取机会的共同承诺。
This agreement positions Kuros for new opportunities in the U.S. spine market and also paves the way for broader adoption of the MagnetOs family of products, which are supported by robust clinical data and innovative designs. This agreement transforms an initial trial agreement into a strategic alliance for a period of five years.
该协议为Kuros在美国脊柱市场提供了新机会，并且为MagnetOs系列产品的更广泛采用铺平了道路，这些产品得到了强有力的临床数据和创新设计的支持。该协议将初步的试用协议转变为为期五年的战略联盟。
Chris Fair, Chief Executive Officer of Kuros Biosciences, commented: "What started as a trial agreement has now evolved into a strategic alliance with Medtronic reflecting an important milestone for Kuros. This agreement will also help us drive the scaling up process, further optimize our operating leverage, and continue our rapid revenue growth both with Medtronic and in our own direct channels."
Kuros Biosciences首席执行官Chris Fair评论道："最初的试用协议如今已经演变为与美敦力的战略联盟，这对Kuros来说是一个重要的里程碑。该协议还将帮助我们推动规模化进程，进一步优化我们的运营杠杆，并继续我们的营业收入快速增长，无论是在美敦力方面，还是在我们自己的直接渠道中。"
For further information, please contact:
如需更多信息，请联系：
Kuros Biosciences AG |
|
Kuros Biosciences AG |
|
About MagnetOs
MagnetOs is a bone graft like no other: thanks to its NeedleGripTM surface technology, it grows bone even in soft tissues. This surface technology provides traction for our body's vitally important 'pro-healing' immune cells (M2 macrophages). This in turn, unlocks previously untapped potential to stimulate stem cells - and form new bone throughout the graft. The growing body of science behind NeedleGrip is called osteoimmunology. But for surgeons and their patients it means one thing: a more predictable fusion.*†‡1-5
关于MagnetOs
MagnetOs是一种独特的骨移植材料：得益于其 NeedleGripTm 表面技术，能够在软组织中生长出骨头。这种表面技术为我们身体至关重要的“促进愈合”免疫细胞（M2巨噬细胞）提供了牵引力。这反过来解锁了以前未开发的潜力，能够刺激干细胞——并在整个移植物中形成新骨。关于 NeedleGrip 的不断增长的科学研究被称为骨免疫学。但对于外科医生和他们的病人来说，这意味着一件事：更可预测的融合。*†‡1-5
Indications statement
Please refer to the instructions for use for your local region for a full list of indications, contraindications, warnings and precautions.
适应症声明
请参考您所在地区的使用说明书，以获取适应症、禁忌症、警告和注意事项的完整列表。
About Kuros Biosciences
Kuros Biosciences is on a mission to discover, develop and deliver innovative biologic technologies. With locations in the United States, Switzerland and the Netherlands, the company is listed on the SIX Swiss Exchange. The company's first commercial product, MagnetOsTM, is a unique advanced bone graft that has already been used across four continents. For more information on the company, its products and pipeline, visit kurosbio.com.
关于Kuros生物科学
Kuros生物科学的使命是发现、开发和交付创新的生物技术。公司在美国、瑞士和荷兰设有办事处，并在瑞士证券交易所上市。公司的第一个商业产品MagnetOsTm是一种独特的先进骨移植材料，已经在四大洲使用。欲了解有关公司、其产品和产品线的更多信息，请访问kurosbio.com。
Forward Looking Statements
This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words "will" or "expect" or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors. Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.
前瞻性声明
本媒体发布包含某些前瞻性陈述，这些陈述涉及风险和不确定性，可能导致实际结果与历史结果或任何未来结果存在重大差异，这些未来结果在此类前瞻性陈述中表示或暗示。我们建议您考虑包含“将”或“期望”以及这些词的否定形式或其他类似词的陈述，这些陈述是不确定和前瞻性的。可能导致实际结果与任何未来结果存在重大差异的因素包括科学、商业、经济和财务因素。在这些不确定性背景下，读者不应依赖前瞻性陈述。公司不承担更新前瞻性陈述或将其调整至未来事件或发展的责任。
* Results from in vivo laboratory testing may not be predictive of clinical experience in humans. For important safety and intended use information please visit kurosbio.com.
† MagnetOs is not cleared by the FDA or TGA as an osteoinductive bone graft.
‡ MagnetOs has been proven to generate more predictable fusions than two commercially available alternatives in an ovine model of posterolateral fusion.
* 体内实验室测试的结果可能无法预测人类的临床体验。有关重要的安全性和预期使用信息，请访问 kurosbio.com。
† MagnetOs 尚未获得 FDA 或 TGA 的批准作为骨诱导骨移植。
‡ MagnetOs 已被证明在一个羔羊的背外侧融合模型中，比两种商业可用的替代品生成更可预测的融合。
1. Van Dijk, et al. eCM. 2021; 41:756-73.
2. Duan, et al. eCM. 2019; 37:60-73.
3. Van Dijk, et al. Clin Spine Surg. 2020;33(6): E276-E287.
4. Van Dijk, et al. JOR Spine. 2018; e1039.
5. Van Dijk, et al. J Biomed Mater Res. Part B: Appl Biomater. 2019;107(6):2080-2090.
1. Van Dijk 等人，eCm. 2021; 41:756-73。
2. Duan 等人，eCm. 2019; 37:60-73。
3. Van Dijk 等人，Clin Spine Surg. 2020;33(6): E276-E287。
4. Van Dijk等。JOR脊柱。2018；e1039。
5. Van Dijk等。生物医学材料研究。第B部分：应用生物材料。2019；107(6)：2080-2090。
SOURCE: Kuros Biosciences AG
来源：Kuros生物科学有限公司
